Helus Pharma cites currency switch, share consolidation and Nasdaq move as key Q1 FY2027 factors for Cybin

Reuters2026/08/14 11:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

For the three months ended June 30, 2026, management commentary centered on corporate changes rather than operating drivers or earnings factors.
Presentation currency shifted to USD to better match expense mix and improve comparability with peers, affecting how results are reported.
U.S. listing moved to Nasdaq under ticker HELP, alongside a shift to operating under the Helus Pharma business name.
Share consolidation of 1-for-38 completed in 2024, with per-share figures retrospectively restated across periods.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Helus Pharma cites currency switch, share consolidation and Nasdaq move as key Q1 FY2027 factors for Cybin

You may also like

Crypto prices